文献速递炎症性肠病

粪便钙卫蛋白与溃疡性结肠炎内镜-组织学缓解的相关性:汇总分析

The Association of Faecal Calprotectin Measurements With Endo-Histological Remission in Ulcerative Colitis: A Pooled Analysis.
PubMed 文献 · Aliment Pharmacol Ther · 2026-06-02

该汇总分析纳入四个学术中心的741例溃疡性结肠炎患者,评估粪便钙卫蛋白(FCAL)预测内镜和组织学活动的最佳阈值。结果显示FCAL对MES 0-1 vs 2-3的AUC为0.802,最佳阈值234.6 μg/g;对GHS<3.1 vs ≥3.1的AUC为0.752,阈值166.2 μg/g。作者提出170 μg/g阈值以最大化敏感性并减少假阴性。

要点

  • FCAL预测内镜活动(MES 0-1 vs 2-3)的AUC为0.802,最佳阈值234.6 μg/g。
  • FCAL预测组织学活动(GHS<3.1 vs ≥3.1)的AUC为0.752,最佳阈值166.2 μg/g。
  • 提出170 μg/g阈值用于MES 0-1 vs 2-3,敏感性0.801,特异性0.648。

核心结论

  • FCAL能以可接受的敏感性和特异性预测UC的内镜和组织学活动,所提阈值有助于指导临床实践。

研究设计与样本

  • 对来自四个学术中心的回顾性和前瞻性UC研究进行汇总分析,纳入741例接受结肠镜检查并测量FCAL的成人UC患者。
  • 使用80%数据通过5折交叉验证计算ROC曲线确定最佳FCAL阈值,并在剩余20%数据中测试。

主要发现

  • MES 0 vs 1-2-3:AUC 0.716(95%CI 0.701-0.731,p<0.0001),最佳阈值154.3 μg/g(特异性0.69,敏感性0.64)。
  • MES 0-1 vs 2-3:AUC 0.802(95%CI 0.797-0.807,p<0.0001),最佳阈值234.6 μg/g(特异性0.74,敏感性0.69)。
  • GHS ≤2.0 vs >2.0:AUC 0.656(95%CI 0.647-0.664,p<0.0001),最佳阈值117.6 μg/g(特异性0.61,敏感性0.59)。
  • GHS <3.1 vs ≥3.1:AUC 0.752(95%CI 0.743-0.762,p<0.0001),最佳阈值166.2 μg/g(特异性0.69,敏感性0.69)。
  • 针对MES 0-1 vs 2-3提出170 μg/g阈值:敏感性0.801(95%CI 0.729-0.873),特异性0.648(95%CI 0.641-0.656),LR+ 2.311,LR- 0.289,准确率67.62%。

关键数值与推荐

  • 内镜活动评估采用MES 0-1 vs 2-3和MES 0 vs 1-3。
  • 组织学活动或缓解评估采用GHS <3.1 vs ≥3.1和GHS ≤2.0 vs >2.0。

临床怎么用

  • FCAL可作为UC内镜和组织学活动的无创预测指标,所提阈值可辅助临床决策。
  • 170 μg/g阈值用于MES 0-1 vs 2-3可最大化敏感性并限制假阴性比例。

局限性

  • 作者指出需要进一步研究验证结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endoscopic and histologic evaluation is part of routine clinical practice to confirm the presence of active disease in ulcerative colitis. Faecal calprotectin (FCAL) levels show a positive correlation with endoscopic indices, relapse, and response to treatment. Existing studies have not clearly determined cut-off values for endoscopic and histologic remissions. AIMS: Our study aims to determine an optimal FCAL threshold for discriminating between endoscopic and histologic active disease and remission in UC, based on the Mayo Endoscopic Score (MES) and the Geboes Histologic Score. METHODS: We performed a pooled analysis of retrospective and prospective studies of patients with UC from four academic centres. Key inclusion criteria were adult UC patients undergoing colonoscopy, with FCAL measurements. Receiver operating characteristic curves were computed on 80% of the data using 5-fold cross-validation to determine the optimal FCAL threshold for predicting active UC based on specificity (spec) and sensitivity. Optimal thresholds were then tested on the remaining 20% of the data. Active endoscopic disease was assessed using MES 0-1 versus 2-3 and MES 0 versus 1-3, and active histologic disease or remission was evaluated using GHS < 3.1 versus GHS ≥ 3.1 and GHS ≤ 2.0 versus GHS > 2.0. RESULTS: A total of 741 patients with UC were included in our analysis. For MES 0 versus 1-2-3, the AUC was 0.716 (95% CI: 0.701-0.731, p < 0.0001) with an optimal threshold of 154.3 μg/g (specificity: 0.69 [95% CI: 0.65-0.72], sensitivity: 0.64 [95% CI: 0.60-0.69]). For MES 0-1 versus 2-3, the AUC increased to 0.802 (95% CI: 0.797-0.807, p < 0.0001), with an optimal FCAL threshold of 234.6 μg/g (specificity: 0.74 [95% CI: 0.74-0.75], sensitivity: 0.69 [95% CI: 0.62-0.75]). For GHS ≤ 2.0 versus GHS > 2.0, the AUC was 0.656 (95% CI: 0.647-0.664, p < 0.0001), with an optimal threshold of 117.6 μg/g (specificity: 0.61 [95% CI: 0.56-0.66], sensitivity: 0.59 [95% CI: 0.56-0.63]). For GHS < 3.1 vs. GHS ≥ 3.1, the AUC was 0.752 (95% CI: 0.743-0.762, p < 0.0001), with an optimal threshold of 166.2 μg/g (specificity: 0.69 [95% CI: 0.66-0.73], sensitivity: 0.69 [95% CI: 0.63-0.76]). Given the high AUC for MES 0-1 vs. MES 2-3, we tested different FCAL thresholds from the literature and propose a threshold of 170 μg/g to maximize sensitivity (sensitivity: 0.801 [95% CI: 0.729-0.873], specificity: 0.648 [95% CI: 0.641-0.656], LR+ 2.311 [95% CI: 2.001-2.670], LR- 0.289 [95% CI: 0.196-0.427], accuracy 67.62% [95% CI: 65.95-69.30]) and limit the proportion of false negatives. CONCLUSIONS: Our study demonstrates that FCAL can predict both active endoscopic and histological disease with acceptable sensitivities and specificities. The proposed cut-off values will help guide clinical practice to achieve the recommended treatment outcomes. Further studies are warranted to validate our results.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Dubé LR, Sorin M, Allez M, et al. The Association of Faecal Calprotectin Measurements With Endo-Histological Remission in Ulcerative Colitis: A Pooled Analysis. Aliment Pharmacol Ther. 2026. PMID: 42227157. doi:10.1111/apt.70735

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。